Trial Profile
A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2011
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 20 Apr 2010 Results have been reported in a UMN Pharma media release.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.